Prilenia: Four regimens fail endpoints simultaneously in HEALEY ALS trial

ALS candidates from Biohaven, Prilenia, Clene and UCB have all failed to halt disease progression versus placebo in the US-wide trial. The post Four regimens fail endpoints simultaneously in HEALEY ALS trial appeared first on Clinical Trials Arena.